SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is trending as its dedicated community actively champions the "We're All Gonna Make It" mantra, positioning the token as a lifestyle and symbol of collective success. The strong sentiment among holders, often linked to the Solana ecosystem, revolves around continuous building and accumulation, anticipating significant long-term potential for this community-driven asset.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is currently trending with strong community enthusiasm, driven by the launch of staking features that reinforce its "pure belief asset" narrative. Members are actively discussing the project as a revolutionary alternative to traditional retirement plans, symbolizing a movement to empower retail investors. This highly engaged community, often comparing itself to past market movements, emphasizes conviction and the goal of early financial freedom.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Crypto is trending as its Wolfpack community celebrates the launch of WolfSWAP, a cross-chain aggregator offering fee-sharing and fostering a decentralized ecosystem. Enthusiasts are strongly bullish on this utility-focused meme coin, highlighting its "never seen before" flagship product slated for early 2026 and positioning it as a major force aiming to redefine the meme coin space. The community emphasizes organic growth and a collective rally against traditional KOL-driven narratives.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume following news of a strategic manufacturing partnership with Syrma Johari, aimed at scaling production of its fingerprint drug screening reader for anticipated U.S. market entry. This has sparked intense community discussion, with many anticipating significant gains and potential for a short squeeze given the stock's low float, while others express caution regarding a recent offering and potential dilution.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending amidst an intense community debate, largely driven by persistent rumors of major partnerships with Mastercard and Walmart that could significantly expand Flexa's real-world crypto payment utility. Despite widespread frustration over its past performance and perceived market manipulation, a dedicated investor base maintains that AMP's existing merchant adoption and underlying technology position it as severely undervalued, especially with impending regulatory clarity from the "Clarity Act." This sentiment reflects a critical balance between immediate market skepticism and long-term conviction in its payment infrastructure.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust ($GBTC) is trending amidst a fierce debate over Bitcoin's current market cycle, with a vocal bearish sentiment predicting an impending "crypto winter" and significant price crash based on historical patterns. Conversely, bullish investors are viewing current levels as a key buying opportunity, anticipating a parabolic rally for Bitcoin, citing strong institutional interest and its role as a digital hedge similar to gold. The asset's trajectory remains a central point of contention as market participants weigh cyclical predictions against broader adoption trends.

Piggy Bank Token

PIGGY CRYPTO is trending due to its unique real-world utility in Korea's phone charging market, employing a "Charge-to-Earn" model, alongside a recent "A-grade" CertiK security audit. The community is buzzing with bullish sentiment, highlighting strong developer efforts, impactful AMAs, and strategic community collaborations, including notable involvement from a former SafeMoon figure. This has fueled discussions around its growth potential and unique reflection-based tokenomics.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending as Bitcoin ETFs face notable outflows, fueling a polarized community discussion about Bitcoin's immediate outlook. Bears anticipate a 'crypto winter' and significant price correction, while bulls argue a 'new cycle theory' and institutional buying will prevent a deep crash, highlighting Bitcoin's role amid broader market risk appetite.

Breaking Bread is a pioneer in Solana meme token designed around a simple and transparent rewards system. With 0% tax on trades, every holder benefits directly from activity without hidden costs or penalties. The token automatically redistributes 100% of creator rewards from Pump.fun back to the community, ensuring fair participation for all holders. The project emphasizes consistency, trust, and community engagement, framing daily “breaking of bread” rewards as both a symbolic ritual and a practical way to sustain value for those who participate.

Breaking Bread

BRBR (Breaking Bread) is captivating the crypto community as a pioneering Solana token offering passive $SOL rewards to holders with zero transaction taxes. Discussions revolve around its innovative 'first of its kind' model, strong community commitment, and consistent chart performance, driving enthusiasm for its long-term potential.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

The iShares Bitcoin ETF, IBIT, is a focal point of intense discussion, driven by a pending Bank of Japan rate decision that could influence Bitcoin's short-term price action, alongside a recent return of positive ETF inflows. Community sentiment is sharply divided between those anticipating a prolonged 'crypto winter' based on historical cycles and others highlighting sustained institutional accumulation and evolving market dynamics as key factors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Autolus Therapeutics (NASDAQ:AUTL) Shares Up 13.5% on Analyst Upgrade

Autolus Therapeutics (NASDAQ:AUTL) Trading Up 13.5% Following Analyst Upgrade...

Autolus Therapeutics (NASDAQ:AUTL) Given New $11.00 Price Target at Needham & Company LLC

Needham & Company LLC upped their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Monday...

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 PR Newswire VANCOUVER, BC, Dec. 19...

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat.com...

TFG Asset Management GP Ltd Has $21.66 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

TFG Asset Management GP Ltd boosted its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 10.5% during the second quarter, according to the company in its most...

Autolus Therapeutics (NASDAQ:AUTL) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Friday...

Armistice Capital LLC Increases Stock Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Armistice Capital LLC raised its holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 9.1% in the second quarter, according to the company in its most recent disclosure...

<ul class="summary-bullets"><li>Aucatzyl will be available through routine commissioning by the NHS, the company said.</li><li>Aucatzyl was approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024.</li><li>The company also intends to launch Aucatzyl in England and Wales soon, It added.</li></ul> Autolus Therapeutics Plc (AUTL) said on Tuesday that the UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending its Aucatzyl CAR T cell therapy for use in the National Health Service (NHS) in England and WalesShares of the company rose 14% in the premarket session at the time of writing.<h2 class="st-heading-2">UK Approval And Recommendation</h2>NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/nice-recommends-aucatzylr-obecabtagene-autoleucel-treatment">said</a>. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia is a cancer that either returns after treatment or never responded to initial therapy.Aucatzyl will be available through routine commissioning by the NHS, the company said. The company also intends to launch Aucatzyl in England and Wales soon, it added.Aucatzyl or obecabtagene autoleucel is an autologous CD19 CAR T cell therapy. Autologous CD19 CAR T-cell therapy is an immunotherapy that uses a patient's own T-cells, which are genetically modified to target and attack cells that express the CD19 protein. This treatment has shown high efficacy in relapsed or refractory B-cell malignancies.The U.S. Food and Drug Administration approved Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024. A conditional marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) followed in April 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AUTL stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘normal’ levels.A Stocktwits user sees the stock hitting as high as $2.50.<stembedurl>https://stocktwits.com/nader_1/message/637361441</stembedurl>Another applauded the recent announcement and expressed hope that cell therapy would become the standard of care.<stembedurl>https://stocktwits.com/janed102/message/637360741</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by 47% this year and by about 58% over the past 12 months. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-keys-stock-surge-14-in-premarket-today/cL52hzFREX8">Why Did KEYS Stock Surge 14% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Equity

Autolus Therapeutics (NASDAQ:AUTL) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Autolus Therapeutics from a "hold" rating to a "strong sell" rating in a report on Saturday...

FY2029 EPS Estimate for Autolus Therapeutics Cut by Analyst

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Analysts at William Blair dropped their FY2029 earnings per share (EPS) estimates for shares of Autolus Therapeutics in a research...

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.23	--	--	N/A
Q3 '25	-$0.21	-$0.30	-39.94%	MISSED
Q2 '25	-$0.23	-$0.18	21.93%	BEAT
Q1 '25	-$0.24	-$0.26	-6.56%	MISSED
Q4 '24	-$0.21	-$0.09	56.26%	BEAT

AUTL
Autolus Therapeutics Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AUTL News

AUTLAutolus Therapeutics Ltd - ADR